Dose Escalation of Biologics in Biologic-Naive Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study.

ABSTRACT:

Background

Dose escalation of biologics may regain treatment response in patients with ulcerative colitis (UC). However, dose escalation rates and associated outcomes and costs are not well characterized in biologic-naïve patients receiving antitumor necrosis factor-alpha (anti-TNF-α) treatments, such as infliximab or adalimumab or vedolizumab.

Methods

ODESSA-UC, a retrospective cohort study investigating dose escalation in patients with UC who had received first-line biologics, used data from IBM MarketScan databases. Adults with UC and ≥1 claim for an index drug (adalimumab, infliximab, or vedolizumab) were eligible. A Cox proportional hazards model was used to evaluate the adjusted rate of dose escalation. Logistic regression was used to evaluate the odds of experiencing

SUBMITTER: Ghosh S 

PROVIDER: S-EPMC10653026 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature